drugset / Trial / NCT07356154
A Study of Revumenib and Mezigdomide in People With Leukemia
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
Timeline
- Start
- 2026-01-16
- Primary completion
- 2029-01-16
- Completion
- 2029-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mezigdomide | Small molecule | — | — |
| Subject | Revumenib | Small molecule | — | — |